Celecoxib, a cyclooxygenase-2 inhibitor, induces apoptosis in human osteosarcoma cell line MG-63 via down-regulation of PI3K/Akt

Cell Biology International

Volumn 32, Issue 5, 2008, Pages 494-501

  Liu, Bing ^a   Shi, Zhong li ^b   Feng, Jie ^b   Tao, Hui min ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b The 2nd Affiliated Hospital   (China)

Author keywords

Apoptosis; Bcl 2; Osteosarcoma; PI3K; Survivin

Indexed keywords

CELECOXIB; CISPLATIN; CYCLOOXYGENASE 1 INHIBITOR; DNA FRAGMENT; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BCL 2; PROTEIN KINASE B; SURVIVIN; WORTMANNIN;

APOPTOSIS; ARTICLE; CELL GROWTH; CONTROLLED STUDY; DRUG INHIBITION; DRUG MECHANISM; HUMAN; HUMAN CELL; OSTEOSARCOMA CELL;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANDROSTADIENES; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CISPLATIN; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; DOWN-REGULATION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; OSTEOSARCOMA; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRAZOLES; SULFONAMIDES;

EID: 43849106469     PISSN: 10656995     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cellbi.2007.10.008     Document Type: Article

References (38)

1. Arico S., Pattingre S., Bauvy C., Gane P., Barbat A., Codogno P., et al. Celecoxib induces apoptosis by inhibiting 3-Phosphoinositide-dependent protein kinese-1 activity in the human colon cancer HT-29 cell line. J Biol Chem 277 (2002) 27613-27621
2. Asanuma H., Torigoe T., Kamiguchi K., Hirohashi Y., Ohmura T., Hirata K., et al. Survivin expression is regulated by coexpression of human epidermal growth factor receptor 2 and epidermal growth factor receptor via phosphatidylinositol 3-Kinase/AKT signaling pathway in breast cancer cells. Cancer Res 65 (2005) 11018-11025
3. Bacci G., Briccoli A., Rocca M., Ferrari S., Donati D., Longhi A., et al. Neoadjuvant chemotherapy for osteosarcomas of the extremities with metastases at presentation: recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide. Ann Oncol 14 (2003) 1126-1134
4. Cantley L.C. The phosphoinositide 3-kinase pathway. Science 296 (2002) 1655-1657
5. Datta S.R., Brunet A., and Greenberg M.E. Cellular survival: a play in three Akts. Genes Dev 13 (1999) 2905-2927
6. Davies N.M., McLachlan A.J., Day R.O., and Williams K.M. Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor. Clin Pharmacokinet 38 (2000) 225-242
7. Dickens D.S., Kozielski R., Khan J., Forus A., and Cripe T.P. Cyclooxygenase-2 expression in pediatric sarcomas. Pediatr Dev Pathol 5 (2002) 356-364
8. Dickens D.S., Kozielski R., Leavey P.J., Timmons C., and Cripe T.P. Cyclooxygenase-2 expression does not correlate with outcome in osteosarcoma or rhabdomyosarcoma. Pediatr Hematol Oncol 25 (2003) 282-285
9. Eberhart C.E., Coffey R.J., Radhika A., Giardiello F.M., Ferrenbach S., and DuBois R.N. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107 (1994) 1183-1188
10. Gately S., and Kerbel R. Therapeutic potential of selective cyclooxygenase-2 inhibitors in the management of tumor angiogenesis. Prog Exp Tumor Res 37 (2003) 179-192
11. Gupta R.A., and Dubois R.N. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 1 (2001) 11-21
12. Hida T., Yatabe Y., Achiwa H., Muramatsu H., Kozaki K., Nakamura S., et al. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 58 (1998) 3761-3764
13. Hwang D., Scollard D., Byrne J., and Levine E. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Natl Cancer Inst 90 (1998) 445-460
14. Kalifa C., Brugieres L., and Le Deley M.C. Neoadjuvant treatment in osteosarcomas. Bull Cancer 93 (2006) 1115-1120
15. Koga H., Sakisaka S., Ohishi M., Kawaguchi T., Taniguchi E., Sasatomi K., et al. Expression of cyclooxygenase-2 in human hepatocellular carcinoma: relevance to tumor dedifferentiation. Hepatology 29 (1999) 688-696
16. Krysan K., Dalwadi H., Sharma S., Pold M., and Dubinett S. Cyclooxygenase 2-dependent expression of survivin is critical for apoptosis resistance in non-small cell lung cancer. Cancer Res 64 (2004) 6359-6362
17. Li F., Ambrosini G., Chu E.Y., Plescia J., Tognin S., Marchisio P.C., et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 396 (1998) 580-584
18. Lin J., Hsiao P.W., Chiu T.H., and Chao J.I. Combination of cyclooxygenase-2 inhibitors and oxaliplatin increases the growth inhibition and death in human colon cancer cells. Biochem Pharmacol 70 (2005) 658-667
19. Masi L., Recenti R., Silvestri S., Pinzani P., Pepi M., Paglierani M., et al. Expression of cyclooxygenase-2 in osteosarcoma of bone. Appl Immunohistochem Mol Morphol 15 (2007) 70-76
20. Mohammed S.I., Craig B.A., Mutsaers A.J., Glickman N.W., Snyder P.W., deGortari A.E., et al. Effects of the cyclooxygenase inhibitor, piroxicam, in combination with chemotherapy on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer. Mol Cancer Ther 2 (2003) 183-188
21. Monick M.M., Robeff P.K., Butler N.S., laherty D.M., Carter A.B., Peterson M.W., et al. Phosphatidylinositol 3-kinase activity negatively regulates stability of cyclooxygenase-2 mRNA. J Biol Chem 277 (2002) 32992-33000
22. Naruse T., Nishida Y., Hosono K., and Ishiguro N. Meloxicam inhibits osteosarcoma growth, invasiveness and metastasis by COX-2-dependent and independent routes. Carcinogenesis 27 (2006) 584-592
23. Nzeako U.C., Guicciardi M.E., Yoon J.H., Bronk S.F., and Gores G.J. COX-2 inhibits Fas-mediate apoptosis in cholangiocarcinoma cells. Hepatology 35 (2002) 552-559
24. Pugazhenthi S., Nesterova A., Sable C., Heidenreich K.A., Boxer L.M., Heasley L.E., et al. Akt/protein kinase B up-regulates Bcl-2 expression through cAMP-response element-binding protein. J Biol Chem 275 (2000) 10761-10766
25. Pyrko P., Soriano N., Kardosh A., Liu Y.T., Uddin J., Petasis N.A., et al. Downregulation of survivin expression and concomitant induction of apoptosis by celecoxib and its non-cyclooxygenase-2-inhibitory analog, dimethyl-celecoxib (DMC), in tumor cells in vitro and in vivo. Mol Cancer 5 (2006) 19
26. Reddig P.J., and Juliano R.L. Clinging to life: cell to matrix adhesion and cell survival. Cancer Metast Rev 24 (2005) 425-439
27. Renard A.J., Veth R.P., Schreuder H.W., Pruszczynski M., Bökkerink J.P., van Hoesel Q.G., et al. Osteosarcoma: oncologic and functional results. A single institutional report covering 22 years. J Surg Oncol 72 (1999) 124-129
28. Samuels Y., Wang Z., Bardelli A., Silliman N., Ptak J., Szabo S., et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 304 (2004) 554
29. Schonthal A.H. Anti-tumor properties of dimethyl-celecoxib, a derivative of celecoxib that does not inhibit cyclooxygenase-2. Neurosurg Focus 20 (2006) 1-10
30. Shin S., Sung B.J., Cho Y.S., Kim H.J., Ha N.C., Hwang J.I., et al. An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7. Biochemistry 40 (2001) 1117-1123
31. Song X., Lin H.P., Johnson A.J., Tseng P.H., Yang Y.T., Kulp S.K., et al. Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells. J Natl Cancer Inst 94 (2002) 585-591
32. Tamm I., Wang Y., Sausville E., Scudiero D.A., Vigna N., Oltersdorf T., et al. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, Caspases, and anticancer drugs. Cancer Res 58 (1998) 5315-5320
33. Tsujii M., and DuBois R.N. Alterations in cellular adhesions and apoptosis in epithelial cells overexpressing prostaglandin endoperoxidase synthase 2. Cell 83 (1995) 493-501
34. Tsujii M., Kawano S., and DuBois R.N. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci U S A 94 (1997) 3336-3340
35. Tsujii M., Kawano S., Tsuji S., Saeaoka H., Hori M., and DuBois R.N. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93 (1998) 705-716
36. Tucker O.N., Dannenberg A.J., Yang E.K., Zhang F., Teng L., Daly J.M., et al. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res 59 (1999) 987-990
37. Waskewich C., Blumenthal R.D., Li H., Stein R., Goldenberg D.M., and Burton J. Celecoxib exhibits the greatest potency amongst cyclooxygenase (COX) inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell lines. Cancer Res 62 (2002) 2029-2033
38. Williams C.S., Watson A.J.M., Sheng H., Helou R., Shao J., and DuBois R.N. Celecoxib prevents tumor growth in vivo without toxicity to normal gut: lack of correlation between in vitro and in vivo models. Cancer Res 60 (2000) 6045-6051